Anaptysbio, Inc (ANAB): Revenue
$234.60M
Year ended 2025-12-31
$232.39M
Trailing 12 months to 2026-03-31
+183.6%
3-year compound annual growth
+25.6%
5-year compound annual growth
+29.6%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $234.60M | +157.0% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $91.28M | +432.0% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $17.16M | +66.8% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $10.29M | -83.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $63.17M | -15.8% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $75.00M | +837.5% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $8.00M | +60.0% | 2022-03-07, From 2019-01-01 |
| 2018-12-31 | $5.00M | -50.0% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $10.00M | -40.1% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $16.68M | -5.0% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $17.57M | n/a | 2018-03-05, From 2015-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $234.60M | +157.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $236.20M | +47.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $228.37M | -0.9% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $244.06M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $247.00M | -4.3% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $218.71M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $216.10M | +8.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $255.87M | +23.3% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $213.65M | -6.5% |
Compare ANAB, AKBA, PBYI, KROS side by side · Screen every company in Pharmaceutical Preparations ↗